1. Calhoun D.A, Jones D., Textor S. et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117(25): 1403–19.
2. Mancia G., De Backer G., Dominiczak A., et al.; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH- ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007;25(9):1751–62.
3. Mancia G., Laurent S., Agabiti-Rosei E., et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27(11):2121–58.
4. Garg JP, Elliott WJ, Folker A et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005; 18 (5 Pt 1): 619–26.
5. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens 2001; 14 (12): 1263–9.
6. Schlaich M., Sobotka P. Krum H. et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009; 54:1195–201.
7. Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet 1953; 1: 403–08.
8. Allen E.V. Sympathectomy for essential hypertension. Circulation 1952; 6(1): 131–140.
9. Smithweek R.H. Splanchnicectomy for essential hypertension. JAMA 1953; 152 (16): 1501–4.
10. Symplicity™ Catheter. Medtronic, Inc., Mountain View, CA; 2010.
11. Rippy M. K., Zarins D., Barman N.C. et al. Catheter-based renal sympathetic denervation: chronic pre- clinical evidence for renal artery safety. Clin Res Cardiol 2011;100(12):1095–101
12. DiBona GF. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hyper- tens 2002; 11: 197–200.
13. Krum H., Schlaich M., Whitbourn R. et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373(9671):1275–81.
14. Krum H, Barman N, Schlaich M, et al.; Symplicity HTN-1 Investigators. Results presented at Euro PCRannual meeting 2013. 21–24 May 2013, Paris.
15. Esler MD, Krum H, Schlaich M et al. Renal sympathetic denervation in patients with treatment resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903– 9.
16. Brandt M.C., Mahfoud F., Reda S. et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012;59(10):901–9.
17. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123: 1940–44.
18. Pokushalov E, Romanov A, Corbucci G et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 2012;60(13):1163–70.
19. Davies JE, Manisty CH, Petraco R et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol 2013;162(3):189– 92.
20. Witkowski A., Prejbisz A., Florczak E. et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58(4):559–65.
21. Global SYMPLICITY Registry. http://clinicaltrials.gov/ct2/show/NCT01534299.
22. Schmieder R.E., Redon J., Grassi G. et al. ESH position paper: renal denervation – an interventional therapy of resistant hypertension. J Hypertens 2012; 30(5):837–41.
